Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-four research firms that are presently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $386.1386.
A number of equities analysts recently issued reports on the stock. Needham & Company LLC decreased their price target on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective on the stock in a research report on Monday, August 3rd. JPMorgan Chase & Co. reduced their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Royal Bank Of Canada lowered their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research note on Friday, July 31st.
View Our Latest Research Report on Alnylam Pharmaceuticals
Insider Transactions at Alnylam Pharmaceuticals
Institutional Trading of Alnylam Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. MV Capital Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $25,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Golden State Wealth Management LLC grew its holdings in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter worth about $29,000. Finally, Manchester Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Stock Down 1.0%
Shares of Alnylam Pharmaceuticals stock opened at $236.56 on Friday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a market cap of $31.65 billion, a P/E ratio of 43.97 and a beta of 0.30. The company’s fifty day simple moving average is $263.44 and its two-hundred day simple moving average is $294.13.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company’s quarterly revenue was up 66.9% compared to the same quarter last year. During the same period last year, the company posted ($0.51) EPS. Research analysts anticipate that Alnylam Pharmaceuticals will post 6.59 EPS for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
